Table 2. Comparison of baseline characteristics of study patients according to occurrence of new lesions 9-month and ≤ 2 years after PCI.
| Variables | New lesion (+) 9-month | New lesion (+) ≤ 2 years | ||||
|---|---|---|---|---|---|---|
|
New lesion (+) group (n = 31) |
New lesion (-) group (n = 506) |
p value |
New lesion (+) group (n = 90) |
New lesion (-) group (n = 447) |
p value | |
| Age, years | 67 [60–76] | 70 [64–77] | 0.58 | 66 [59–75] | 70 [64–77] | 0.006 |
| Sex: male, n (%) | 22 (71) | 370 (73) | 0.83 | 67 (74) | 325 (73) | 0.73 |
| Body mass index, kg/m2 | 24.3 [20.9–25.9] | 23.8 [21.5–26.1] | 0.78 | 23.8 [21.6–26.3] | 23.9 [21.5–26.1] | 0.52 |
| Risk factors, n (%) | ||||||
| Hypertension | 26 (84) | 412 (81) | 0.71 | 73 (81) | 365 (82) | 0.90 |
| Diabetes mellitus | 19 (61) | 294 (58) | 0.85 | 62 (69) | 251 (56) | 0.025 |
| Dyslipidemia | 22 (71) | 386 (76) | 0.52 | 68 (76) | 340 (76) | 0.92 |
| Current smoker | 2 (6) | 61 (12) | 0.36 | 13 (14) | 50 (11) | 0.36 |
| History of smoking | 18 (58) | 63 (12) | ＜0.001 | 18 (20) | 63 (14) | 0.20 |
| Medication, n (%) | ||||||
| Oral anticoagulation | 6 (19) | 59 (12) | 0.25 | 13 (14) | 52 (12) | 0.46 |
| Calcium-channel blocker | 18 (58) | 211 (42) | 0.98 | 42 (47) | 187 (42) | 0.40 |
| ACEI | 4 (13) | 97 (19) | 0.48 | 14 (16) | 87 (19) | 0.39 |
| ARB | 18 (58) | 207 (41) | 0.064 | 39 (43) | 186 (42) | 0.76 |
| β-blocker | 20 (66) | 165 (33) | ＜0.001 | 31 (34) | 154 (34) | 0.99 |
| Ezetimibe | 1 (3) | 39 (8) | 0.72 | 6 (7) | 34 (8) | 0.99 |
| Nitrates | 4 (13) | 46 (9) | 0.52 | 7 (8) | 43 (10) | 0.69 |
| Proton pump inhibitor | 18 (58) | 257 (51) | 0.46 | 48 (53) | 214 (48) | 0.34 |
| Laboratory data | ||||||
| Hemoglobin, g/dL | 12.9±1.8 | 13.0±2.0 | 0.47 | 13.2±1.8 | 12.9±2.0 | 0.179 |
| hs-CRP, mg/L | 1.6 [0.6–2.4] | 1.2 [0.4–3.3] | 0.65 | 1.7 [0.6–3.7] | 1.1 [0.4–3.1] | 0.159 |
| TC, mg/dL | 174 [141–196] | 154 [135–178] | 0.028 | 168 [140–197] | 153 [135–176] | 0.001 |
| LDL-C (F) ≥ 70 mg/dL, n (%) | 25 (81) | 323 (64) | 0.040 | 68 (76) | 280 (63) | 0.019 |
| LDL-C (M) ≥ 70 mg/dL, n (%) | 26 (84) | 346 (68) | 0.048 | 71 (79) | 301 (67) | 0.030 |
| HDL-C ＜40 mg/dL, n (%) | 7 (23) | 126 (25) | 0.68 | 25 (28) | 108 (24) | 0.47 |
| Non-HDL-C ≥ 100 mg/dL, n (%) | 23 (74) | 281 (56) | 0.030 | 63 (70) | 241 (54) | 0.005 |
| TG ≥ 150 mg/dL, n (%) | 8 (26) | 133 (26) | 0.99 | 25 (28) | 116 (26) | 0.69 |
| Uric acid, mg/dL | 6.2 [4.7–6.6] | 5.9 [5.0–6.8] | 0.70 | 6.1 [4.8–6.7] | 5.9 [5.0–6.8] | 0.99 |
| FPG, mg/dL | 106 [91–129] | 111 [96–134] | 0.108 | 116 [95–135] | 109 [96–133] | 0.31 |
| eGFR, mL/min/1.73 m2 | 65.4 [56.5–76.9] | 61.1 [47.2–74.7] | 0.135 | 64.9 [50.9–77.8] | 59.7 [47.2–74.1] | 0.065 |
| LVEF, % | 59 [50–66] | 58[49–66] | 0.94 | 57.7 [50.8–66.2] | 58.3 [47.9–66.2] | 0.76 |
Abbreviations are as in Table 1